Biogen Inc Asset Resilience Ratio
Biogen Inc asset resilience ratio. Biogen Inc (BIIB) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Biogen Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biogen Inc (1994–2025)
Asset resilience ratio of Biogen Inc from 1994 to 2025. This chart shows how Biogen Inc's Asset Resilience Ratio has changed over time. Read Biogen Inc (BIIB) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Biogen Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biogen Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biogen Inc Industry Peers by Asset Resilience Ratio
Compare Biogen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Biogen Inc Asset Resilience Ratio by Year (1994–2025)
Biogen Inc asset resilience ratio by year from 1994 to 2025. The table below shows the annual Asset Resilience Ratio data for Biogen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.74% | $807.20 Million | $29.44 Billion | -- |
| 2024-12-31 | 0.00% | $0.00 | $28.05 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $26.84 Billion | -- |
| 2022-12-31 | 6.00% | $1.47 Billion | $24.55 Billion | -0.45pp |
| 2021-12-31 | 6.45% | $1.54 Billion | $23.88 Billion | +1.26pp |
| 2020-12-31 | 5.19% | $1.28 Billion | $24.62 Billion | -0.54pp |
| 2019-12-31 | 5.74% | $1.56 Billion | $27.23 Billion | -3.41pp |
| 2018-12-31 | 9.15% | $2.31 Billion | $25.29 Billion | +0.21pp |
| 2017-12-31 | 8.94% | $2.12 Billion | $23.65 Billion | -2.29pp |
| 2016-12-31 | 11.23% | $2.57 Billion | $22.88 Billion | +0.36pp |
| 2015-12-31 | 10.87% | $2.12 Billion | $19.50 Billion | +6.40pp |
| 2014-12-31 | 4.47% | $640.46 Million | $14.32 Billion | -0.75pp |
| 2013-12-31 | 5.23% | $620.17 Million | $11.86 Billion | -5.98pp |
| 2012-12-31 | 11.20% | $1.13 Billion | $10.13 Billion | -1.79pp |
| 2011-12-31 | 13.00% | $1.18 Billion | $9.05 Billion | +7.46pp |
| 2010-12-31 | 5.54% | $448.15 Million | $8.09 Billion | -2.44pp |
| 2009-12-31 | 7.97% | $681.84 Million | $8.55 Billion | -0.86pp |
| 2008-12-31 | 8.83% | $749.03 Million | $8.48 Billion | +2.76pp |
| 2007-12-31 | 6.07% | $523.84 Million | $8.63 Billion | +3.25pp |
| 2006-12-31 | 2.82% | $241.31 Million | $8.55 Billion | -0.56pp |
| 2005-12-31 | 3.38% | $282.58 Million | $8.37 Billion | -5.88pp |
| 2004-12-31 | 9.26% | $848.50 Million | $9.17 Billion | +3.77pp |
| 2003-12-31 | 5.48% | $521.11 Million | $9.50 Billion | -35.47pp |
| 2002-12-31 | 40.96% | $822.00 Million | $2.01 Billion | -2.28pp |
| 2001-12-31 | 43.23% | $744.07 Million | $1.72 Billion | -1.02pp |
| 2000-12-31 | 44.26% | $633.67 Million | $1.43 Billion | -2.51pp |
| 1999-12-31 | 46.76% | $597.62 Million | $1.28 Billion | -6.39pp |
| 1998-12-31 | 53.15% | $491.47 Million | $924.72 Million | +7.72pp |
| 1997-12-31 | 45.43% | $369.73 Million | $813.83 Million | +4.56pp |
| 1996-12-31 | 40.87% | $259.35 Million | $634.57 Million | -15.01pp |
| 1995-12-31 | 55.88% | $262.18 Million | $469.20 Million | -0.52pp |
| 1994-12-31 | 56.40% | $213.12 Million | $377.86 Million | -- |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psorias… Read more